Pancreatic Cancer Research

ResearcherHirosaki UniversityActive in the last 2 years

Kenichi Hakamada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6513-1202; OpenAlex author ID A5002019305. Sources: OpenAlex.

Their work

Papers
33 (first author 1, last author 22)
Trials
0
Grants
0
Labs led
1
Collaborators
99
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: none · 2021: 7 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 33

  1. Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2026.106238↗
  2. Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Prop… Last author DOI 10.1016/j.jss.2026.08.063↗
  3. MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer. Last author DOI 10.1016/j.modpat.2025.100953↗
  4. Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy. Last author DOI 10.1097/mpa.0000000000002706↗
  5. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  8. Noninvasive Computed Tomography-Based Deep Learning Model Predicts In Vitro Chemosensitivity Assay Results in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002270↗
  9. Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer: A propensity score matching analysis. Last author DOI 10.3892/ol.2024.14369↗
  10. Dual epigenetic changes in diabetes mellitus-associated pancreatic ductal adenocarcinoma correlate with downregulation of E-cadherin and worsened prognosis. Last author DOI 10.1002/cjp2.326↗
  11. Diabetes mellitus impacts on expression of DNA mismatch repair protein PMS2 and tumor microenvironment in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jdi.13929↗
  12. Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemothera… Co-author DOI 10.3892/or.2023.8498↗
  13. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Re… Last author DOI 10.1245/s10434-021-10920-3↗
  14. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12379↗
  15. Roles of the nervous system in pancreatic cancer. Last author DOI 10.1002/ags3.12459↗
  16. The Cell Line-Dependent Diversity in Initial Morphological Dynamics of Pancreatic Cancer Cell Peritoneal Metastasis Visualized by an Artificial Human Peritonea… Last author DOI 10.1016/j.jss.2020.12.046↗
  17. Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer. Last author DOI 10.1038/s41598-021-00727-3↗
  18. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching A… Last author DOI 10.1097/mpa.0000000000001913↗
  19. Diabetes in Humans Activates Pancreatic Stellate Cells via RAGE in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms222111716↗
  20. Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. Co-author DOI 10.3892/ol.2021.12537↗
  21. Cancer stroma-targeting therapy: A new tool for fighting pancreatic cancer? Co-author DOI 10.1002/ags3.12244↗
  22. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppress… Last author DOI 10.1097/mpa.0000000000001211↗
  23. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  24. [A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery]. Last author PMID 32156995↗
  25. [A Case of Remnant Pancreatic Cancer after Conversion Surgery for Advanced Distal Bile Duct Cancer Treated with Chemotherapy]. Last author PMID 30692392↗
  26. 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells. Last author DOI 10.1097/mpa.0000000000000741↗
  27. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms18030600↗
  28. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Last author DOI 10.3892/mco.2017.1251↗
  29. Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. Last author DOI 10.3892/ol.2016.4930↗
  30. [Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy]. Last author PMID 24393952↗
  31. The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.3892/ijo.2012.1559↗
  32. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.21880↗
  33. Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer. Last author DOI 10.3892/ol.2011.412↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keinosuke Ishido · 20 shared papers, 2011–2026 · strength 3.15
  2. Hayato Nagase · 12 shared papers, 2016–2026 · strength 2.06
  3. Taiichi Wakiya · 10 shared papers, 2013–2026 · strength 1.59
  4. Yusuke Wakasa · 4 shared papers, 2018–2026 · strength 1.01
  5. Taishu Kanda · 6 shared papers, 2021–2024 · strength 0.98
  6. Satoru Tsuruta · 3 shared papers, 2026 · strength 0.93
  7. Tadashi Yoshizawa · 5 shared papers, 2021–2026 · strength 0.87
  8. Yutaro Hara · 5 shared papers, 2021–2026 · strength 0.86
  9. Hiroshi Kijima · 6 shared papers, 2011–2026 · strength 0.75
  10. Keisuke Yamazaki · 3 shared papers, 2023–2026 · strength 0.58
  11. Sohei Satoi · 4 shared papers, 2019–2025 · strength 0.58
  12. Itaru Endo · 4 shared papers, 2019–2025 · strength 0.58
  13. Daisuke Kudo · 8 shared papers, 2011–2019 · strength 0.58
  14. Shintaro Goto · 3 shared papers, 2021–2026 · strength 0.58
  15. Satoshi Hirano · 3 shared papers, 2025 · strength 0.50
  16. Eri Yoshida · 4 shared papers, 2016–2024 · strength 0.43
  17. Kenta Ogasawara · 2 shared papers, 2023–2026 · strength 0.43
  18. Tsutomu Fujii · 3 shared papers, 2019–2025 · strength 0.42
  19. Masaaki Hidaka · 2 shared papers, 2025 · strength 0.35
  20. Masamichi Mizuma · 2 shared papers, 2025 · strength 0.35
  21. Hiroshi Kurahara · 2 shared papers, 2025 · strength 0.35
  22. Goro Honda · 2 shared papers, 2025 · strength 0.35
  23. Michiaki Unno · 2 shared papers, 2025 · strength 0.34
  24. Shugo Mizuno · 2 shared papers, 2025 · strength 0.32
  25. Shuji Suzuki · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.